TNF-ALPHA

Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability
Declan F McCole

Gut May 2023, 72 (5) 814-815; DOI: 10.1136/gutjnl-2022-327599
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study
Daniel Ward, Mikael Andersson, Nynne Nyboe Andersen, Kristine Højgaard Allin, Laurent Beaugerie, Tine Jess, Julien Kirchgesner

Gut Nov 2022, 71 (11) 2373-2374; DOI: 10.1136/gutjnl-2021-326462
The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
Thomas X Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba

Gut Nov 2021, 70 (11) 2076-2084; DOI: 10.1136/gutjnl-2020-321609
Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
Yuri Gorelik, Shay Freilich, Shiran Gerassy-Vainberg, Sigal Pressman, Chagit Friss, Alexandera Blatt, Gili Focht, Yiska Loewenberg Weisband, Shira Greenfeld, Revital Kariv, Nathan Lederman, Iris Dotan, Naama Geva-Zatorsky, Shai Shlomo Shen-Orr, Yechezkel Kashi, Yehuda Chowers

Gut Feb 2022, 71 (2) 287-295; DOI: 10.1136/gutjnl-2021-325185
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach
Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg

Gut Apr 2021, 70 (4) 812-813; DOI: 10.1136/gutjnl-2020-322302
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Geert R D'Haens, Sander van Deventer

Gut Jul 2021, 70 (7) 1396-1405; DOI: 10.1136/gutjnl-2019-320022
Very early-life exposure to microbiota-induced TNF drives the maturation of neonatal pre-cDC1
Arnaud Köhler, Sandrine Delbauve, Justine Smout, David Torres, Véronique Flamand

Gut Mar 2021, 70 (3) 511-521; DOI: 10.1136/gutjnl-2019-319700
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Remo Panaccione, Jean-Frederic Colombel, Simon P L Travis, Peter Bossuyt, Filip Baert, Tomáš Vaňásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Walter Reinisch, Scott Johnson, Marric Buessing, Ezequiel Neimark, Joel Petersson, Wan-Ju Lee, Geert R D’Haens

Gut Apr 2020, 69 (4) 658-664; DOI: 10.1136/gutjnl-2019-318256
TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn’s disease patients?
Bram Verstockt, Sare Verstockt, Helene Blevi, Isabelle Cleynen, Magali de Bruyn, Gert Van Assche, Séverine Vermeire, Marc Ferrante

Gut Aug 2019, 68 (8) 1531-1533; DOI: 10.1136/gutjnl-2018-316845
Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
Renaud Gaujoux, Elina Starosvetsky, Naama Maimon, Francesco Vallania, Haggai Bar-Yoseph, Sigal Pressman, Roni Weisshof, Idan Goren, Keren Rabinowitz, Matti Waterman, Henit Yanai, Iris Dotan, Edmond Sabo, Yehuda Chowers, Purvesh Khatri, Shai S Shen-Orr

Gut Apr 2019, 68 (4) 604-614; DOI: 10.1136/gutjnl-2017-315494

Main menu

TNF-ALPHA

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

TNF-ALPHA

Pages